Find a Clinical Trial

Changes in Skeletal Muscle Thickness in Patients with Acute Heart Failure

18-100

Learn more

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-01)

A phase 3 randomized, open-label study of OP-1250 monotherapy vs standard of care for the treatment of ER+, HER2– advanced or metastatic breast cancer following endocrine and CDK 4/6 inhibitor therapy (OPERA-01)

18+

Learn more

AGENT IDE

A Prospective, Randomized (2:1), Multicenter Trial to Assess the Safety and Effectiveness of the AgentTM Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects with In-Stent Restenosis (ISR)

18+

Learn more

TAP Block and minimally invasive hysterectomy for pain control

A randomized, controlled, observer-blinded pilot trial of laparoscopic large volume, multisite transversus abdominal plane (TAP) block with liposomal bupivacaine in patients undergoing minimally invasive hysterectomy for endometrial cancer

18-80

Learn more

A Safety and Feasibility Study of Percutaneous Delivery of an Arterial VA-ECMO Cannula into the Aorta

A Safety and Feasibility Study of Percutaneous Delivery of an Arterial VA-ECMO Cannula into the Aorta

18-75

Learn more

ASTRID-HF

A SkeleTal muscle Recovery Intervention with Dietary protein in Heart Failure (ASTRID-HF)

18-100

Learn more

Acute Hemodynamics in Patients on AMCS

Acute Hemodynamics in Patients on AMCS

18+

Learn more

Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis

Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis

60+

Learn more

Breast Cancer Database

Breast Cancer Database

18+

Learn more

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1)

CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence

18+

Learn more